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Abstract
Pemphigus represents a group of organ specific autoimmune blistering disorders of the skin 
mediated by pathogenic autoantibodies with well-defined antigenic targets. While most of these 
diseases are sporadic, endemic forms of disease do exist. The endemic form of pemphigus 
foliaceus (also known as fogo selvagem, FS) exhibits epidemiological features that suggest 
exposure to hematophagous insect bites are a possible precipitating factor of this autoimmune 
disease, and provides a unique opportunity to study how environmental factors contribute to 
autoimmune disease development. FS patients and healthy individuals from endemic regions show 
an autoreactive IgM response that starts in early childhood and becomes restricted to IgG4 
autoantibodies in FS patients. In searching for triggering environmental antigens, we have found 
that IgG4 and IgE autoantibodies from FS patients cross-react with a salivary antigen from sand 
flies. The presence of these cross-reactive antibodies and antibody genetic analysis confirming that 
these antibodies evolve from the same naïve B cells provides compelling evidence that this non-
infectious environmental antigen could be the initial target of the autoantibody response in FS. 
Consequently, FS serves as an ideal model to study the impact of environmental antigens in the 
development of autoimmune disease.
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Introduction
Pemphigus encompasses a group of autoimmune blistering diseases of the skin and mucosa. 
Pemphigus foliaceus (PF) and pemphigus vulgaris (PV) are the two major phenotypes of 
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pemphigus [1, 2]. Clinically, PF affects only the skin, whereas PV initially affects mucous 
membranes (mucosal PV) and later involves the skin (mucocutaneous PV) [1, 3, 4]. The 
hallmark of all pemphigus phenotypes is the presence of intraepidermal vesicles [1] and 
anti-epidermal autoantibodies [2, 3, 5-7]. The anti-epidermal autoantibodies are detected 
bound to the surface of detached keratinocytes in lesional epidermis and circulating in the 
serum of patients [7]. It has been well demonstrated that these anti-epidermal autoantibodies 
recognize desmogleins (Dsg), a family of desmosomal cell adhesion glycoproteins [1, 2, 
5-7]. The desmosome is a cell-cell adhesion organelle present in keratinocytes and other 
squamous epithelial cells [8], and consists of core and plaque structural components. The 
core contains transmembrane glycoproteins including desmogleins and desmocollins that 
belong to the cadherin superfamily [9, 10]. In humans, four desmogleins have been 
identified, namely Dsg 1, 2, 3, and 4 and they share high degree of sequence homology 
[9-16]. Immunologically, the sera of PF patients show anti-Dsg1 antibodies while the sera of 
PV patients contain antibodies to both Dsg1 and Dsg3 [2, 3, 6]. PV and PF in North 
America are sporadic [1, 6], but an endemic form of PF is described in certain states of 
Brazil, where it is known as Fogo Selvagem (FS) [17, 18]. FS shows similar clinical, 
histological and immunological features to those observed in non-endemic PF [19, 20].
The Terena Reservation of Limao Verde (LV), Brazil, in particular, has a 3.4% prevalence 
rate of FS [21]. Epidemiologic and immunogenetic studies suggest that both genetic and 
environmental factors contribute to the development of FS [17, 22, 23]. Genetically, FS 
exhibits a strong association with the HLA-DRB1*0102, 0404 and 1402 alleles (p<0.005, 
RR: 14) and affects people of many races and ethnic backgrounds [22]. Inbreeding, which is 
a common practice in the endemic areas, may compound the likelihood that genetically 
predisposed individuals will pass these traits to their offspring. Approximately 93% of 
familial cases of FS were found in genetically related individuals [24]. While the genetic 
factors that contribute to disease development are known, the environmental antigens 
triggering disease development is an evolving field of study.
The term “Exposome” has recently been introduced to describe the environmental factors 
that are associated with the initiation of autoimmune diseases [25, 26]. Environmental 
factors include airborne, oral, and percutaneous exposures and may be infectious or 
noninfectious in nature. The association of infectious agents with the development of 
autoimmune diseases has been well studied [25, 27-30], and the term “infectome” has been 
proposed to describe the link between external environmental infectious antigens and the 
initiation of autoimmune diseases [25-27]. Compared to the studies of the infectious agents, 
the study of non-infectious environmental antigens and their association with the 
development of autoimmune diseases is limited. Unlike infectious antigens that induce a 
robust IgG immune response, low doses of non-infectious antigens, e.g. allergens, usually 
induce IgE and IgG4 responses, especially if the routes of exposure are via skin or mucosa. 
Using the endemic autoimmune skin disease FS as a model, we have identified a possible 
non-infectious antigen(s) that may initiate this autoimmune skin disease. We propose a 
model in which non-infectious environmental antigens which cross-react with Dsg1 first 
induce an IgE response and then trigger the IgG4 autoantibody response that eventually 
leads to FS in these genetically susceptible individuals.
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IgG4 and IgE autoantibodies in autoimmune skin diseases
Since the initial observation of Jones et al [31] on the IgG subclass restriction of PV 
autoantibodies to the IgG4 and IgG1 subclasses, several studies have confirmed and 
extended these findings using indirect immunofluorescence (IF) assays [32-34]. The IgG 
subclass restriction has been additionally confirmed by ELISA studies using recombinant 
Dsg3 and Dsg1 [35-38]. Studies on PV suggest that IgG4 anti-Dsg3 autoantibodies are 
pathogenic [37, 39]. This IgG subclass restriction is also observed in PF and FS. In 1989 
Rock et al demonstrated through passive transfer experiments in mice that the pathogenic 
IgG response in FS is predominantly IgG4 [40]. A subsequent study using FS sera collected 
longitudinally showed that progression from preclinical to clinical stage of the disease is 
associated with a dramatic rise in IgG4 anti-Dsg1 autoantibodies [41]. Testing of larger 
cohorts of FS and normal control sera confirmed this observation and established a novel 
“IgG4-based classifier” [42]. The positive predictive value of the “IgG4-based classifier” is 
approximately 50%, and can identify individuals in the preclinical stage of FS.
It is well known that increased levels of IgE antibodies are found in human allergic 
responses, but the role that IgE plays in autoimmune skin diseases has only recently been 
investigated. Increased levels of IgE antibodies have been well described in patients with 
bullous pemphigoid (BP), another autoimmune blistering disorder with distinct histology, 
immunofluorescence, and pathophysiology [43-47]. The pathogenic role of autoantigen-
specific IgE in BP has been systematically studied by the Fairley [48, 49] and Zone [50] 
groups. However, early studies on the IgE autoantibody response in pemphigus are sparse. 
These initial studies do suggest that IgE autoantibodies are present in some pemphigus 
patients [43, 51]. In FS patients, potential infestation by intestinal parasites was suggested as 
an explanation for the presence of IgE antibodies among these patients [51]. Later, Spaeth et 
al [52] tested 41 PV patients’ sera for IgG subclasses, IgA and IgE autoantibodies against 
the recombinant Dsg3 ectodomain by immunoblotting and found IgE anti-Dsg3 
autoantibodies in 4 patients. Nagel et al. [53] conducted a comprehensive study on 93 PV 
patients regarding their IgE and IgG4 anti-Dsg3 levels. They found that IgE and IgG4 anti-
Dsg3 correlate with disease activity in PV patients and closely associate with active PV [53]. 
Taken together, these findings along with the known restriction of pathogenic autoantibodies 
to the IgG4 subclass suggest a possible relationship between the IgG4 and IgE responses in 
FS.
Indeed, our studies have revealed that FS patients have significantly higher levels of IgE 
anti-Dsg1 antibodies compared to healthy control individuals from both FS endemic regions 
and the US, and the levels of IgE anti-Dsg1 correlate with those of anti-Dsg1 IgG4 [54]. 
Interestingly, the IgE anti-Dsg1 levels from FS patients are also significantly higher than 
those of PF patients from US and Japan, suggesting there is a difference between FS 
endemic regions from non-FS endemic regions [54]. Moreover, the sera of FS patients 
during the pre-clinical and clinical stages of the disease have higher than normal levels of 
IgE cross-reactive antibodies against self Dsg1 and a sand fly antigen [54-56]. These 
findings collectively bolster the argument that an environmental exposure may trigger the 
development of FS.
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The link between allergy and autoimmunity
Aside from immunodeficiency, the other two main outcomes of a dysfunctional immune 
system are allergy and autoimmunity. It is well accepted that different mechanisms govern 
these two harmful immune responses. However, growing evidence suggests there may be 
some connections between the development of these two abnormalities [57]. Allergic and 
autoimmune conditions can coincide in some patients, suggesting the two abnormalities 
share a common pathophysiologic mechanism [57]. For example, children with rheumatoid 
arthritis and celiac disease have higher incidence of asthma [58, 59]. The allergens that IgE 
target in atopic patients can be either exogenous (allergens) or endogenous (autoantigens) 
[60, 61]. IgE antibodies from atopic dermatitis patients react with human protein [62], and 
several allergens display shared epitopes with human self-proteins [63, 64]. Using serum 
from atopic dermatitis patients, IgE reactive human autoantigens have been isolated from a 
human epithelial cDNA expression library. Importantly, these autoantigens are expressed 
predominantly in the target organs of atopic dermatitis (skin, lung, etc.) [65, 66].
A link between allergy and autoimmunity are the antibodies, i.e. IgG4 and IgE that are 
involved in these two processes. The presence of autoantibodies in allergic diseases suggests 
that an autoimmune response may be playing a role in the pathogenesis of these illnesses 
[57]. An IgE antibody response is the hallmark in allergic diseases, whereas a parallel IgG4 
response may be an attempt to block the allergen-induced inflammation, which is observed 
during the course of allergen-specific immunotherapy [67]. These observations were 
confirmed and extended by Gleich et al [68] demonstrating the reciprocal serum values of 
IgE and IgG4 antibodies in pollen-sensitive patients during the course of immunotherapy 
[69]. The levels of IgE decreased as the levels of IgG4 increased during the months 
following immunotherapy. Similar observations have been made from immunotherapy of 
patients with bee venom hypersensitivity [70] and from heavily exposed beekeepers where 
there is chronic antigenic stimulation [71]. It has been hypothesized that IgG4 “blocking” 
antibodies may exert their beneficial effect by mechanisms, such as: a) competition with IgE 
for antigenic sites on the allergen [72, 73], b) binding Fc receptors on immune cells 
(macrophages, B cells, neutrophils, mast cells and basophils) thus triggering 
immunomodulatory events [74], and c) behaving as anti-idiotypic antibodies. These diverse 
effector functions of blocking antibodies may depend on the avidity for the allergen of these 
molecules. Production of IgG4 antibodies and the decrease of allergen-specific IgE may be 
modulated by IL-10, which is produced by T cells exposed to the allergen during 
immunotherapy [75, 76]. Interestingly, IgG4 antibodies are the main pathogenic 
autoantibodies in autoimmune skin diseases, such as pemphigus foliaceus/Fogo selvagem 
[40], pemphigus vulgaris [77], bullous pemphigoid as detailed above [78]. Importantly, these 
IgG4 anti-Dsg1 and anti-Dsg3 autoantibodies in PF/FS and PV are pathogenic by passive 
transfer into mice, recapitulating the human skin disease in the animals [37, 39, 40]. In 
addition, IgG4 antibodies are also present in numerous autoimmune diseases, including 
autoimmune pancreatitis [79], Mikulicz’s disease (primary Sjogren’s syndrome) [80], as 
well as the newly defined IgG4-related diseases [81-83]. Besides the link between IgE and 
IgG4 antibodies in allergy and autoimmunity, the regulation of the immune system may also 
connect allergy and autoimmunity. It is suggested that allergy may “relax” the regulation of 
self-reactive B cells and lead to the autoimmune response [84]. It was also determined that 
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the polymorphism and dysfunction of transcription factor BACH2 is associated with both 
allergic and autoimmune diseases [85].
The close relationship between the development of IgE and IgG4 antibodies in humans may 
be due to the sequential isotype switch from IgM through IgG4 to IgE [86]. The class switch 
of both isotypes is promoted by Th2 cytokines, such as IL-4 and IL-13. However, chronic 
antigenic stimulation induces secretion of IL-10 which shifts the balance of the class switch 
towards IgG4 [87] (Fig. 1). Divergence of IgE to IgG4 is beneficial to patients with allergies. 
However, in autoimmune skin diseases such as FS, this process may trigger a more robust 
IgG response, which ultimately leads to the generation of pathogenic IgG4 autoantibodies. 
Thus, it is possible that an environmental “allergen” triggers IgE response in FS, and the 
antibodies directed against this “allergen” cross-react with epidermal Dsg1.
Hematophagous insect bites as environmental risk factors in FS
The most intriguing question in autoantibody-mediated autoimmune diseases is what 
triggers the generation of self-reactive antibodies. FS affects people of all races and 
ethnicities and is clustered in rural and impoverished communities. FS is endemic to Brazil, 
but endemic forms of PF have been reported in other countries such as Colombia, and 
Tunisia [23]. In Brazil, people settled in endemic areas and living in rustic houses with 
thatched roofs and walls, tend to develop FS [23]. Two Amerindian reservations in Brazil 
(the Terena reservation of Limao Verde located in the state of Mato Grosso do Sul, and the 
Xavante Reservation located in the state of Mato Grosso) show a high prevalence of FS. The 
majority of individuals in these communities are dedicated to outdoor activities such as 
farming, shrub and tree removal. These human settlements are usually live in close 
proximity to rivers [23]. The inhabitants are constantly exposed to hematophagous insect 
bites, such as black flies (simuliids), sand flies (phlebotomines), or kissing bugs 
(triatomines). Interestingly, the endemic regions where FS occurs, such as Limao Verde, 
overlap with endemic regions of Leishmaniasis (sand flies) and Chagas disease [88].
To further study the link between hematophagous insect bites and the occurrence of 
autoantibodies against Dsg1, we tested several cohorts of sera from FS and other tropical 
diseases including onchocerciasis, leishmaniasis, Chagas disease and blastomycosis [88]. 
We found that sera from patients where an insect vector is involved in the transmission of 
the disease, show anti-Dsg1 antibodies, as compared with other tropical diseases [88]. It 
should be noted that sera from FS patients do not recognize antigens from the parasites 
causing the respective tropical diseases (leishmaniasis and Chagas), suggesting that anti-
Dsg1 antibodies found in these patients may recognize antigens from the saliva of the insect 
vector [88]. Based on the results we hypothesized that the saliva from the hematophagous 
insects could be the source of antigens that trigger cross-reactive autoantibody responses to 
Dsg1 in FS patients.
Antigen-selection of autoantibody development during and before the onset of FS
Analysis of the V gene sequences of the autoantibodies in pemphigus has yielded important 
clues for the development of anti-Dsg1 and anti-Dsg3 antibodies in these patients [89-94]. 
For example, our group and others have found that the development of anti-Dsg3 antibodies 
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in PV is an antigen-driven response [90, 94]. We also analyzed the H and L chain V genes of 
anti-Dsg1 IgM and IgG antibodies from 8 FS patients and an healthy individual before the 
onset of clinical FS (pre-FS) [92]. Besides the overwhelming evidence that the development 
of anti-Dsg1 autoantibodies in FS are antigen-driven, we have also found that the generation 
of anti-Dsg1 autoantibodies in pre-FS individuals is also antigen selected [92]. This is 
evident not only from the shared VH chain V gene usage and shared amino acid replacement 
mutations among these anti-Dsg1 autoantibodies, but also that 10 out of 20 autoantibody H 
chains show significant evidence of antigen selection in the pre-FS individual [92] based on 
the multinomial model for antigen selection analysis [95]. Because this individual did not 
have active disease at the time of the blood sample collection, the source of the selecting 
antigens were most likely from the exposure to the environmental antigens, further 
suggesting the presence of FS associated environmental antigens in FS endemic regions. It 
should be noted that V genes of these anti-Dsg1 autoantibodies from both FS patients and 
the pre-FS individual shared some of the same replacement mutations, suggesting that they 
may be selected by the same environmental- or self-antigen(s) [92].
Distinctive autoreactive IgM antibodies in FS
IgM antibodies are considered to be responsible for the primary immune response against 
infectious and noninfectious exogenous antigens, and increased levels of IgM (hyper-IgM) 
in autoimmune diseases are well documented in the literature [96]. It is interesting that a 
significant number of FS patients and healthy individuals living in endemic areas have IgM 
anti-Dsg1 as compared with PF patients and healthy controls from either US or Japan [97]. 
There is no evidence that PF or FS patients have a defect in immunoglobulin class switch 
[98].
The higher frequency of IgM anti-Dsg1 in FS patients and healthy individuals from endemic 
areas is likely due to the environmental differences between FS endemic and non-FS 
endemic regions. It has been reported that FS patients transferred to urban hospitals away 
from their native environment, show a lower frequency of IgM anti-Dsg1, possibly due to 
the elimination of environmental antigenic exposure [97]. Ongoing prospective sero-
epidemiological studies of three cohorts composed of children and adolescents from Limao 
Verde show that IgM anti-Dsg1 antibodies are present in children as young as five years of 
age [97], but IgM anti-Dsg1 antibodies are absent in the cord sera of neonates from mothers 
from Limao Verde [99]. We were able to document the rise in IgG and pathogenic IgG4 anti-
Dsg1 autoantibodies during the transition from the pre-clinical to the clinical stage of FS. 
These findings suggest the existence of an environmental antigen(s) in endemic areas that 
sensitizes and triggers anti-Dsg1 autoantibody formation in these individuals.
There are numerous possibilities that could explain the presence of persistent IgM 
autoantibodies in these individuals, such as the presence of IgM memory B cells [100]. Due 
to the unique environment that surrounds the individuals settled in these communities, it is 
likely that the high level of anti-Dsg1 IgM in FS patients and healthy individuals is due to 
polyclonal activation of IgM memory B cells [101]. This observation appears to be 
confirmed in our studies regarding the antigen selection of anti-Dsg1 antibodies in FS and a 
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pre-FS individual. We find that less IgM anti-Dsg1 antibodies are antigen selected as 
compared to those of IgG anti-Dsg1 antibodies in FS patients and a pre-FS individual [92].
IgE and IgG4 responses to a non-infectious environmental antigen in FS endemic regions
Detection of high levels of IgE anti-Dsg1 in FS patients suggest an ongoing exposure to an 
environmental sensitizing antigen(s) which is present in regions where these patients live 
[54]. Based on our serological studies on anti-Dsg1 response in patients with insect-borne 
tropical diseases such as leishmaniasis and Chagas disease [88], we have begun dissect the 
IgG reactivity of FS IgG and IgG4, containing anti-Dsg1 antibodies, against well-
characterized salivary antigens for Lutzomya longipalpis [102-104]. Our studies demonstrate 
that FS patients have both IgE and IgG4 antibodies against sand fly salivary gland antigens 
(SGLL). The levels of IgG4 anti-SGLL antibodies significantly correlate with the that of 
IgG4 anti-Dsg1 autoantibodies, suggesting that IgG4 reacts to both exogenous and 
endogenous antigens might be due to the cross-reactivity of these IgG4 antibodies [55]. The 
levels of IgG4 anti-SGLL also significantly correlate with that of IgE anti-SGLL, implying 
that there is a parallel development of IgG4 and IgE against the same environmental antigens 
which is similar to those observed in the chronic allergen stimulation and allergy 
immunotherapy [71]. Further testing using FS sera against main components from SGLL 
recognized by human, LJM11, LJM17, and LJL143 indicated that the LJM11 component 
from sand fly is the primary target for FS IgG4 antibodies [55]. The LJM11 antigen, a 
member of the “yellow family” of salivary proteins is the most immunogenic component 
among the sand fly saliva proteins and is also a marker for human exposure to sand fly bites 
[103]. Two IgG4 monoclonal anti-Dsg1 antibodies isolated from FS patients cross-react to 
both Dsg1 and LJM11 antigens [55]. Furthermore, mice immunized with LJM11, but not 
LJM17 and LJL143, develop a strong humoral response to human Dsg1 [55]. All these 
evidence strongly suggest the existence of a “cross-reactive” epitope(s) on both LJM11 and 
Dsg1. Thus, it is possible that IgE and IgG4 responses directed against the “cross-reactive” 
epitope(s) initiates the generation of IgG4 autoantibodies in FS susceptible individuals due 
to the chronic stimulation of non-infectious antigen (LJM11) present in FS endemic regions.
IgE antibodies against environmental antigens may be an early marker for the FS 
development
It is apparent that IgE anti-LJM11 antibodies are widely present in FS patients [55]. We next 
explored whether IgE anti-Dsg1 and anti-LJM11 antibodies develop in individuals before 
the onset of their FS. If it were the case, it would be an indication that they may play an 
etiological role in the development of autoantibodies and subsequent FS. The development 
of IgE anti-environmental antigen before the onset of FS would be a useful marker for early 
detection of individuals at risk of developing FS. We studied samples collected from 
individuals living in the FS endemic region over many years. We tested serum samples from 
12 FS individuals prior to their onset of clinical FS (1 to 4 years), as well as after the 
development of clinical FS, to determine their serum anti-Dsg1 and anti-LJM11 IgE levels. 
Compared to normal controls from both LV and US, individuals before and after their onset 
of FS have significantly higher IgE anti-LJM11 antibodies [56]. There are also significantly 
higher anti-Dsg1 IgE levels in individuals before and after their onset of FS than normal 
controls from both LV and US. These results suggest that the IgE antibodies develop well 
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before the onset of FS (as early as 4 years before) among FS susceptible individuals. 
However, in contrast to the comparable IgE anti-LJM11 levels from individuals before and 
after the onset of FS, pre-FS individuals have significantly lower levels of anti-Dsg1 IgE 
before their onset of FS than after [56]. It indicates that anti-LJM11 antibodies developed 
earlier in those individuals than that of anti-Dsg1 IgE, suggesting that LJM11 might be the 
initial target of IgE response. Interestingly, even there is no significant difference between 
IgE anti-Dsg1 levels of normal controls from both FS (LV) and non-FS (US) endemic 
regions, normal controls from LV have significantly higher IgE anti-LJM11 antibodies than 
those from US (p<0.01) [56]. These findings again support that there are environmental 
differences between these two geographic areas.
Coinciding development of IgG4 antibodies reactive to environmental antigen and 
autoantigen in FS
A critical question that needs to be answered in any given immune response is whether the 
response represents non-specific activation of the immune system or an antigen-selected 
response [105]. Our earlier studies on the autoreactive IgM and IgG antibodies from FS 
patients indicate that most of the IgG anti-Dsg1 antibodies are antigen selected [92]. 
However, only two IgG4 monoclonal antibodies, the major subclass of pathogenic 
autoantibodies in FS, were identified using the hybridoma method, despite the fact that 
several thousands of hybridomas being screened. Thus, we cannot conclusively state IgG4 
autoantibodies are also antigen selected. To further dissect the IgG4 antibody repertoires and 
the nature of the IgG4 antibody response in FS, we modified the original antibody phage 
display method [106] to isolate only IgG4 antibodies from FS patient blood samples [107]. 
Since the antibody phage display libraries that we generate comprise only IgG4 subclass 
from patients, we can focus on isolating only the potential pathogenic IgG4 antibodies from 
FS patients. Using this modified antibody phage display method, 136 IgG4 monoclonal 
antibodies were isolated from three FS patient samples, including 14 clonally independent 
IgG4 monoclonal antibodies [107]. Among them, two IgG4 monoclonal antibodies 
originally isolated by hybridoma method were also identified [92, 107]. This method may 
prove to be a very useful tool for the study of IgG4 antibody repertoires and the mechanism 
by which IgG4 antibodies develop in patients with the newly categorized IgG4-related 
diseases [81-83].
As demonstrated, FS patients have IgG4 anti-LJM11 antigen from sand fly saliva, in 
addition to IgG4 anti-Dsg1 [55, 56]. We sought to further determine if the IgG4 anti-Dsg1 
and – LJM11 responses in FS patients are associated. We panned the IgG4 antibody phage 
display libraries against both Dsg1 and LJM11 antigens [107]. The IgG4 antibody responses 
towards these two antigens could yield three possible outcomes (Fig. 2). The most likely 
scenario is that immune responses to either Dsg1 or LJM11 have their own population of 
IgG4 antibodies, but that the two populations have significant overlap (Fig. 2, outcome 1). 
There are also two other possible outcomes. First, IgG4 responses to Dsg1 and LJM11 are 
independent (Fig. 2, outcome 2). Our previous studies [55] indicate that there are cross-
reactive antibodies from FS patients, making it unlikely that IgG4 responses to both 
molecules are completely independent. Second, the IgG4 responses to Dsg1 and LJM11 are 
the same and all the IgG4 antibodies isolated from panning against Dsg1 or LJM11 are 
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cross-reactive (Fig. 2, outcome 3). Dsg1 and LJM11 are evolutionary distant molecules and 
share little primary sequence homology. Furthermore, the cross-reactive monoclonal 
antibodies from FS bind both molecules via conformational epitope [55]. Therefore, the 
chance that all the conformational epitopes on both molecules are the same seems unlikely. 
The analysis of the IgG4 antibodies directed against either Dsg1 or LJM11 enabled us to 
disclose the degree of the overlap between these two IgG4 responses, and as a result, the 
significance of how IgG4 response to environmental antigens contributes to the development 
of IgG4 autoreactive antibodies in FS.
Based on the H chain complementary determining region 3 (CDR3) sequence identity, or 
“clonal signature” [108], whether a group of IgG4 antibodies are derived from the same 
parental B cells, or whether they are clonally related, could be conclusively determined 
[107]. The analyses of the H chain V genes and the clonal signature of all identified IgG4 
monoclonal antibodies from the panning of these three IgG4 antibody phage display 
libraries indicated that they could be grouped into a 14 lineages of clones (that originated 
from the same parental B cells) according to their CDR3 clonal signatures [107]. All of 
these IgG4 monoclonal antibodies are cross-reactive to both Dsg1 and LJM11 as determined 
by either Dsg1/LJM11 alternate panning, anti-Dsg1 and anti-LJM11 ELISA, or both [107]. 
It seems that the findings from panning of the IgG4 antibody phage display libraries fit the 
Outcome 3 shown in Fig 2. However, as elucidated above, it is unlikely that all IgG4 
antibodies from FS are cross-reactive to both Dsg1 and LJM11. The possible explanations 
are, 1. The panning of IgG4 phage display libraries only captures those abundant IgG4 
antibodies, while rare clones (Dsg1 or LJM11 specific or not cross-reactive) escape 
detection [107]; 2. The IgG4 antibodies identified from IgG4 phage display libraries only 
represent those IgG4 committed B cells in patient blood samples, but not those terminally 
differentiated plasma cells in FS patients that secrete IgG4 autoantibodies that represent the 
IgG4 antibodies in patients’ sera.
Another finding is that all monoclonal antibodies isolated from the libraries are extensively 
mutated as their homology to their germline V genes are low. Replacement mutations in the 
complementary determining regions are significantly higher compared to the framework 
regions, which harbor mostly silent mutations [107]. Thus, similar to our earlier studies that 
anti-Dsg1 IgG autoantibodies are antigen selected [92], these potential pathogenic IgG4 
antibodies in FS are also antigen selected [107]. Furthermore, revertant monoclonal 
antibodies, which represent the germline configuration (expressed by naïve B cells) of these 
cross-reactive monoclonal antibodies, also recognize both Dsg1 and LJM11 [107]. 
Collectively, this evidence strongly suggests that LJM11 is an inciting environmental antigen 
that activates the naïve B cells for the succeeding autoantibody development and ensuing FS 
among FS-susceptible individuals in FS endemic regions. However, our findings regarding 
the role of LJM11 as an environmental antigen does not exclude in any way that other 
environmental antigens present in FS endemic regions could also serve as inciting antigens 
for the development of FS.
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Conclusion
Taken together, our extensive studies on FS patients and healthy individuals living in 
endemic areas allow us to draw several lines of evidence that point to salivary gland protein 
components from the sand fly, as the trigger of FS. These studies, using FS as a model of an 
environmentally induced autoimmune disease, demonstrate that non-infectious antigens can 
precipitate harmful autoantibodies to the host. Antigen-mimicry may play an important role. 
The possible mechanism by which environmental antigens could trigger the development of 
anti-Dsg1 in FS-susceptible individuals is depicted in Fig. 3. The environmental antigen 
(such as LJM11) as an inciting antigen stimulates naïve B cells to undergo class switch and 
generates the initial IgE response directed against LJM11. Because of the presence of 
“cross-reactive” epitopes on LJM11 and Dsg1, the initial antibody response, such as IgE 
response, also reacts to Dsg1. The chronic stimulation of LJM11 antigen and the production 
of IL10 by the immune system promotes the development of IgG4 antibodies, which are also 
cross-reactive to both LJM11 and Dsg1. Those IgG4 antibodies are either pathogenic in FS, 
or they trigger the further development of IgG4 autoantibodies via epitope spreading [109] 
to develop pathogenic autoantibodies and subsequent FS in susceptible individuals. Our 
findings support the hypothesis that non-infectious environmental antigens may trigger 
autoimmune disease and pave the way for similar studies in other autoimmune diseases.
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Take-home messages
• Non-endemic pemphigus foliaceus (PF) and endemic pemphigus 
foliaceus (Fogo Selvagem, FS) are epidermal-specific autoimmune skin 
diseases mediated by IgG4 autoantibodies.
• Insect bites are a major risk factor for the development of FS. The 
salivary components of hematophagous insects could serve as the 
environmental trigger for the development of autoantibodies and 
subsequent FS among susceptible individuals in endemic regions.
• IgG4 and IgE autoantibodies from FS patients cross-react with LJM11 
antigen, a salivary protein component from sand fly. Sand fly is the 
vector of leishmaniasis that is also prevalent in FS endemic regions.
• Salivary components, such as LJM11 from sand fly, from indigenous 
insects could serve as non-infectious environmental antigens that 
induce IgE response to individuals living in FS endemic regions.
• Both IgE and IgG4 responses are promoted by Th2 cytokines. IgG4 
autoantibody development in FS patients could be the result of initial 
IgE response to the non-infectious environmental antigens, due to the 
developmental association between IgG4 and IgE antibodies during 
chronic antigenic stimulation.
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Figure 1. IgE to IgG4 shift during acute-to-chronic transition of immune response to 
environmental antigens or allergens
Sequential class switch from IgM to IgE via IgG4 under the regulation of Th2 cytokines. 
Under the chronic stimulation of allergen, IL-10 shifts the class switch in favor of IgG4.
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Figure 2. 
Three possible outcomes of IgG4 responses to Dsg1 autoantigen and LJM11 environmental 
antigen.
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Figure 3. Environmental antigens (such as LJM11) as inciting antigens trigger the development 
of cross-reactive antibody response and subsequent FS in susceptible individuals
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